Eli Lilly Announces $3.5B Pennsylvania Plant Amid Domestic Expansion

New facility will produce injectable drugs and devices, including weight-loss treatment retatrutide.

Jan. 30, 2026 at 11:39am

Got story updates? Submit your updates here. ›

Drugmaker Eli Lilly and Co. announced plans to build a $3.5 billion manufacturing facility in Fogelsville, Pennsylvania, just outside of Allentown. The new plant will produce injectable drugs and devices, including the company's weight-loss drug retatrutide, which is still under development. The investment is part of a broader domestic expansion for Eli Lilly, which has also announced new facilities in Texas, Virginia, Alabama, and Indiana.

Why it matters

Eli Lilly's expansion comes as the company experiences surging sales of its obesity and diabetes treatments, including Zepbound and Mounjaro. The new Pennsylvania plant will help the drugmaker meet growing demand for its injectable medications and capitalize on the booming market for weight-loss drugs.

The details

The new Eli Lilly facility in Fogelsville, Pennsylvania will focus on producing injectable drugs and devices, including the company's experimental weight-loss treatment retatrutide. Construction on the $3.5 billion plant is expected to begin this year and be completed by 2031. The investment is part of a broader domestic expansion for Eli Lilly, which has also announced new manufacturing sites in Texas, Virginia, Alabama, and Indiana.

  • Construction on the new Eli Lilly plant in Fogelsville, Pennsylvania is expected to begin in 2023.
  • The Fogelsville facility is slated for completion in 2031.

The players

Eli Lilly and Co.

An American pharmaceutical company and one of the largest drugmakers in the world, headquartered in Indianapolis, Indiana.

Zepbound

Eli Lilly's weight-loss treatment drug.

Mounjaro

Eli Lilly's diabetes drug.

Retatrutide

Eli Lilly's experimental once-a-week injectable weight-loss drug that is still under development.

Got photos? Submit your photos here. ›

What’s next

Eli Lilly plans to begin construction on the new Fogelsville, Pennsylvania plant in 2023, with completion expected by 2031.

The takeaway

Eli Lilly's $3.5 billion investment in a new manufacturing facility in Pennsylvania is part of the company's broader strategy to expand domestic production and capitalize on the growing demand for its innovative obesity and diabetes treatments.